Injectsense develops implantable sensors that continuously measure intraocular pressure (IOP) and is also building sensors for intracranial pressure and future cardiovascular pressure monitoring. Its sister company Injectpower produces ultra-miniature solid-state lithium-ion microbatteries for medical implants. The two companies raised combined funding to advance clinical studies, finalize product development, and ready Injectpower’s technology for production. Injectsense is moving into first-in-human IOP studies (February 2024) and is ramping manufacturing from hundreds of prototypes toward thousands in 2024. The companies plan to bring integrated autonomous implantable devices — smaller than a grain of rice — to production and to consolidate a medical device cluster in France to streamline supply chain and business opportunities. Injectsense has provided sensors for animal testing at Johns Hopkins’ Wilmer Eye Institute and used recent NIH funding for its latest sensor iteration. The planned final product, iOP-Connect™, is intended to provide continuous 24/7 IOP measurement over decades with weekly recharging, data uploads, and clinician-specified actionable analytics. Injectsense has developed an ocular implant smaller than a grain of rice that wirelessly and continuously measures intraocular pressure. The device is delivered via a short, non‑surgical injection, can be recharged by wearing paired glasses for five minutes weekly, and the company says the battery pattern can last up to 80 years. Injectsense’s implant has so far been tested in rabbits with no ocular issues reported and successful implantation. The company earned an FDA breakthrough device designation in 2020, and in March received a two‑year $1.7M SBIR grant from the National Eye Institute to support further work. Those funds will support additional animal and bench testing at the Johns Hopkins Wilmer Eye Institute and help inform a human pilot study planned in Chile. Injectsense was founded in 2014, has raised $15 million to date, and is in the process of raising a Series C.

Total raised

$11M

Funding rounds

3

Latest round

Convertible Note

Latest activity

Nov 2023